entertainment -WSS

entertainment

author：leisure time 2025-10-01 17:06:06 - browse：38

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Multiple sclerosis has subtypes with different best treatments: study

leisure time

WSS

Scientific mystery highlights the blind spots in genomics databases

Hundreds died while taking an arthritis drug, but nobody alerted patients

How Vertex's cystic fibrosis drug is changing patients' lives

Republican states more likely to report Covid vaccine side effects

Study: Black kids more likely to die after surgery than white kids

CommonSpirit Health keeps growing, even as it loses money

hotspot

entertainment

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

FDA panel to weigh approval of NurOwn, controversial ALS drug

Affirmative action in medical school literally saved lives

Senate HELP committee spars over health care workforce policies

Guidelines to prevent youth baseball injuries need more muscle

UnitedHealth, in a surprise, takes aim at Steward’s physician group

23andMe had bad news about my health. I wish a person had delivered it

First Opinion on colorectal cancer screening: letter and response

Activists slam private health insurers over coverage restrictions

Alzheimer's risk factor APOE4 may be a distinct form of the disease

explore

Readout LOUD podcast: possible new ALS drug, artificial wombs

Medicare Advantage 2025 payments will dip, Biden administration says

Lasker Awards 2023: Winners in biomedical research

FDA panel to weigh approval of NurOwn, controversial ALS drug

Medicare Advantage 2025 payments will dip, Biden administration says

Biotech stock slump in 2023: awaiting the turnaround

focus

leisure time

entertainment

hotspot